Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
a monocenter, open label, single arm, phase II study of the combination of axitinib with
avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic
RCC.